EOLS

AI Memo

Evolus

As of 2026-08-25/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-25 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

Potential Evolysse Sculpt U.S. approval • 2026-12-31

Base target: $10 / p=50% prob

Biggest risk

The company remains GAAP-loss-making, cash declined during Q2, tariff uncertainty persists, and key portfolio expansion depends on regulatory and development milestones with long timelines.

Invalidation

Break below $7 or thesis failure.

What would change my mind?

Commercial momentum is improving, with 21% Q2 revenue growth, positive adjusted EBITDA, market-share gains, expanding Evolysse adoption, and a raised 2026 outlook [#SEC-8K-2026-08-05].

Research note

Recommendation

—

Confidence

medium

As of

2026-08-25

Base target

$10

p=50%

Bull target

$12

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q2 execution and raised FY2026 outlook
Portfolio and international expansion
Commercial momentum is improving, with 21% Q2 revenue growth, positive adjusted EBITDA, market-share gains, expanding Evolysse adoption, and a raised 2026 outlook [#SEC-8K-2026-08-05].

BearKey bullets

Cash declined from $49.8 million at Q1-end to $45.2 million at Q2-end while the company continues investing in expansion.
Evolysse Sculpt approval could be delayed or not achieved [#SEC-8K-2026-05-04].
Low analyst coverage and unavailable post-print market-reaction, options, short-interest, and social data limit conviction.

WatchKey bullets

Potential Evolysse Sculpt U.S.

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $10 (p=50%)

Target spread vs base: +20% / -27%

Scenario probabilities

Bull Target: $12 (p=25%)Base Target: $10 (p=50%)Bear Target: $7 (p=25%)

Commentary

Primary-source tone is constructive after Q2, but the evidence set is low coverage and lacks reliable social, options, short-interest, employee, analyst-revision, and post-print reaction data. The result is a cautious monitoring thesis rather than a high-conviction rerating call.

As of 2026-08-25 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Commercial momentum is improving, with 21% Q2 revenue growth, positive adjusted EBITDA, market-share gains, expanding Evolysse adoption, and a raised 2026 outlook [#SEC-8K-2026-08-05].

Bear Case

The company remains GAAP-loss-making, cash declined during Q2, tariff uncertainty persists, and key portfolio expansion depends on regulatory and development milestones with long timelines.

Drivers

Scannable catalysts and supporting factors

Q2 execution and raised FY2026 outlook
Portfolio and international expansion

Scenarios

Bull Target (Scenario probability)

$12 / p=25% prob

Base Target (Scenario probability)

$10 / p=50% prob

Bear Target (Scenario probability)

$7 / p=25% prob

Analysis 2026-08-25 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.65

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
Potential Evolysse Sculpt U.S. approval
Management continued to anticipate U.S. approval of Evolysse Sculpt later in 2026. Approval would broaden the commercial portfolio, while delay would pressure the growth thesis [#SEC-8K-2026-05-04].
Prob 55.00% • Move 18.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

Q2 execution and raised FY2026 outlook
2026-08-31
Q2 revenue rose 21% to $84.1 million, adjusted EBITDA was positive at $4.7 million for the third consecutive quarter, and management raised 2026 revenue and adjusted gross-margin guidance. Continued execution could support a cautious rerating [#SEC-8K-2026-08-05].
Prob 70% • Move 10% • Priced-in 65%

Long-term Catalysts

Months to a year

Portfolio and international expansion
2028-12-31
Evolus added Profhilo through an IBSA partnership, launched Estyme in Europe, and expanded rights into Canada, Australia, and New Zealand. Profhilo commercialization is anticipated around 2030, while the expanded international rights target commercialization in 2028 [#SEC-8K-2026-08-05].
Prob 40% • Move 30% • Priced-in 20%

Risks

Cash declined from $49.8 million at Q1-end to $45.2 million at Q2-end while the company continues investing in expansion.
Evolysse Sculpt approval could be delayed or not achieved [#SEC-8K-2026-05-04].
Low analyst coverage and unavailable post-print market-reaction, options, short-interest, and social data limit conviction.
Profhilo requires a long U.S. development and regulatory path, with commercialization anticipated around 2030 [#SEC-SEC-8K-2026-08-05].
Tariff uncertainty and precautionary inventory actions could pressure working capital and margins.

Peers

Symbol	Summary
AMGN	Large diversified biopharma benchmark; useful for sector risk appetite and scale context but not a direct aesthetics comparable.
GILD	Large diversified biopharma benchmark with limited operating comparability to Evolus's cash-pay aesthetics portfolio.
CCCC	Similar-market-cap healthcare reference, but a clinical biotech rather than a commercial aesthetics business; loose comparator only.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-25

Loading AI feed…

Symbol

Summary

AMGN

Large diversified biopharma benchmark; useful for sector risk appetite and scale context but not a direct aesthetics comparable.

GILD

Large diversified biopharma benchmark with limited operating comparability to Evolus's cash-pay aesthetics portfolio.

CCCC

Similar-market-cap healthcare reference, but a clinical biotech rather than a commercial aesthetics business; loose comparator only.